Tag Archives: Novartis

Commentary: Novartis CEO: Gene therapy offers hope of cures in a treatment, but US needs new pricing, payment model

We live in an incredible era of progress in human health. Advances in cell and gene therapies are beginning to yield powerful new treatments for some of the most devastating illnesses. With many of these new therapies we are no longer combating diseases over time, but potentially curing them in a single treatment. This is… Read More »

Novartis’ Kisqali takes step back in heated market after NICE no vote

With sales of its breast cancer drug Kisqali lagging, Novartis saw an opening in the U.K. market to gain ground on its competitors. Now that door has swung shut. In draft guidance published Wednesday, the National Institute for Health and Care Excellence (NICE) chose not to recommend Kisqali (ribociclib) for treatment of women with hormone… Read More »

Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

Novartis released some new data on CAR-T drug Kymriah this month that it hopes will improve the uptake of the drug. But Novartis also continues to wrestle with manufacturing issues that have kept some doses from meeting specifications, a problem that is also hampering Kymriah sales. The drugmaker says it is working on a list… Read More »